Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t
British Journal of Dermatology2017Vol. 178(5), pp. 1083–1101
Citations Over TimeTop 1% of 2017 papers
Marjolein de Bruin‐Weller, Diamant Thaçi, Catherine Smith, Kristian Reich, Michael J. Cork, Allen Radin, Q. Zhang, Bolanle Akinlade, A. Gadkari, Laurent Eckert, Thomas Hultsch, Z. Chen, Gianluca Pirozzi, Neil M.H. Graham, Brad Shumel
Abstract
Dupilumab + TCS significantly improved signs and symptoms of atopic dermatitis and QoL in adults with a history of inadequate response to/intolerance of CsA, or for whom CsA treatment was medically inadvisable. No new safety signals were identified.
Related Papers
- → Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients(2024)8 cited
- Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK.(2021)
- → The Use of Dupilumab in Severe Atopic Dermatitis During Pregnancy: A Case Report(2021)1 cited
- → A Systemic Review of Dupilumab Efficacy and Safety by Phenotypic Variations of Atopic Dermatitis(2021)